BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Polycythemia Vera readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Polycythemia Vera\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06985147-10341@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:DISC-3405: Phase 2 readout est. (NCT06985147)
DESCRIPTION:DISC-3405\, phase 2\, Polycythemia Vera.\nStudy: A Phase 2\, Op
 en-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)\nE
 stimated primary completion: July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/disc-3405#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06985147
URL:https://assetmemo.bio/drug/disc-3405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644211-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT04644211)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Polycythemia Vera.\nStudy: Rux
 olitinib in Thrombocythemia and Polycythemia Vera\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rux
 olitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04644211
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648030-10912@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:rusfertide: Phase 2 readout est. (NCT07648030)
DESCRIPTION:rusfertide\, phase 2\, Polycythemia Vera.\nStudy: A Study of Ru
 sfertide in Japanese Adults With Polycythemia Vera\nEstimated primary comp
 letion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rusfertide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07648030
URL:https://assetmemo.bio/drug/rusfertide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04282187-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT04282187)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: Decitab
 ine With Ruxolitinib\, Fedratinib or Pacritinib for the Treatment of Accel
 erated/Blast Phase Myeloproliferative Neoplasms\nEstimated primary complet
 ion: 11 November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04282187
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02577926-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02577926)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Polycythemia Vera.\nStudy: The
  Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk
  Essential Thrombocythemia\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0257792
 6
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05870475-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05870475)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Polycythemia Vera.\nStudy: Peg
 ylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydro
 xyurea-resistant/Intolerant PV\nEstimated primary completion: 31 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 70475
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765602-10912@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:rusfertide: Phase 2 readout est. (NCT07765602)
DESCRIPTION:rusfertide\, phase 2\, Polycythemia Vera.\nStudy: A Study of Ru
 sfertide in Adults With Polycythemia Vera in China\nEstimated primary comp
 letion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rusfertide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07765602
URL:https://assetmemo.bio/drug/rusfertide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04116502-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT04116502)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3\, Polycythemia Vera.\nStudy: MIT
 HRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line T
 herapy in High Risk Polycythemia Vera\nEstimated primary completion: 31 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitin
 ib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04116502
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734077-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07734077)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Revum
 enib in Patients With Myelofibrosis\nEstimated primary completion: 1 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib
 -jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07734077
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06327100-7619@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06327100)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Open 
 Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosi
 s (PMF)\, Post-Polycythemia Vera Myelofibrosis (Post-PV MF)\, or Post-Esse
 ntial Thrombocytosis Myelofibrosis (Post-ET MF)\nEstimated primary complet
 ion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxo
 litinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06327100
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
